Tower Research Capital (TRC)’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $632K | Buy |
43,730
+41,367
| +1,751% | +$593K | 0.02% | 761 |
|
|
2025
Q4 | $33.6K | Sell |
2,363
-10,236
| -81% | -$101K | ﹤0.01% | 2721 |
|
|
2025
Q3 | $99.3K | Sell |
12,599
-11,472
| -48% | -$81.6K | ﹤0.01% | 1998 |
|
|
2025
Q2 | $138K | Buy |
24,071
+19,393
| +415% | +$125K | ﹤0.01% | 2116 |
|
|
2025
Q1 | $38.2K | Sell |
4,678
-53,397
| -92% | -$494K | ﹤0.01% | 2419 |
|
|
2024
Q4 | $547K | Buy |
58,075
+46,886
| +419% | +$487K | 0.01% | 997 |
|
|
2024
Q3 | $119K | Sell |
11,189
-46,484
| -81% | -$506K | ﹤0.01% | 2092 |
|
|
2024
Q2 | $572K | Buy |
57,673
+55,420
| +2,460% | +$569K | 0.01% | 1226 |
|
|
2024
Q1 | $26.5K | Sell |
2,253
-24,499
| -92% | -$313K | ﹤0.01% | 2753 |
|
|
2023
Q4 | $380K | Buy |
26,752
+4,511
| +20% | +$51.2K | ﹤0.01% | 1597 |
|
|
2023
Q3 | $270K | Buy |
22,241
+9,700
| +77% | +$125K | 0.01% | 1246 |
|
|
2023
Q2 | $158K | Sell |
12,541
-6,839
| -35% | -$81.2K | 0.01% | 1726 |
|
|
2023
Q1 | $215K | Buy |
19,380
+16,400
| +550% | +$202K | 0.01% | 1332 |
|
|
2022
Q4 | $37K | Sell |
2,980
-85,229
| -97% | -$959K | ﹤0.01% | 2561 |
|
|
2022
Q3 | $921K | Buy |
88,209
+40,419
| +85% | +$450K | 0.02% | 742 |
|
|
2022
Q2 | $514K | Buy |
47,790
+11,508
| +32% | +$94.8K | 0.01% | 1122 |
|
|
2022
Q1 | $343K | Buy |
36,282
+15,034
| +71% | +$141K | ﹤0.01% | 1391 |
|
|
2021
Q4 | $245K | Sell |
21,248
-24,925
| -54% | -$278K | ﹤0.01% | 1606 |
|
|
2021
Q3 | $441K | Buy |
46,173
+25,793
| +127% | +$264K | 0.01% | 1081 |
|
|
2021
Q2 | $197K | Sell |
20,380
-8,943
| -30% | -$87.3K | 0.01% | 1938 |
|
|
2021
Q1 | $289K | Buy |
29,323
+4,015
| +16% | +$62.1K | ﹤0.01% | 1691 |
|
|
2020
Q4 | $584K | Buy |
25,308
+16,746
| +196% | +$342K | 0.02% | 882 |
|
|
2020
Q3 | $121K | Sell |
8,562
-18,862
| -69% | -$275K | ﹤0.01% | 2995 |
|
|
2020
Q2 | $414K | Buy |
+27,424
| New | +$334K | 0.02% | 1184 |
|
|
2020
Q1 | – | Sell |
-12,346
| Closed | -$120K | – | 3309 |
|
|
2019
Q4 | $120K | Buy |
12,346
+12,246
| +12,246% | +$112K | 0.01% | 834 |
|
|
2019
Q3 | $1K | Buy |
+100
| New | +$1.08K | ﹤0.01% | 3854 |
|
|
2018
Q4 | – | Sell |
-13,192
| Closed | -$159K | – | 3978 |
|
|
2018
Q3 | $159K | Buy |
+13,192
| New | +$184K | 0.01% | 1107 |
|
|
2018
Q1 | – | Sell |
-944
| Closed | -$14K | – | 3447 |
|
|
2017
Q4 | $14K | Sell |
944
-4,934
| -84% | -$67.8K | ﹤0.01% | 2315 |
|
|
2017
Q3 | $89K | Buy |
5,878
+5,843
| +16,694% | +$77.3K | 0.01% | 1468 |
|
|
2017
Q2 | $0 | Buy |
35
+8
| +30% | +$64 | ﹤0.01% | 2955 |
|
|
2017
Q1 | $0 | Sell |
27
-2,313
| -99% | -$14.6K | ﹤0.01% | 3319 |
|
|
2016
Q4 | $12K | Buy |
+2,340
| New | +$16.2K | ﹤0.01% | 2521 |
|
|
2016
Q1 | – | Sell |
-9,064
| Closed | -$88K | – | 4378 |
|
|
2015
Q4 | $88K | Buy |
+9,064
| New | +$81.7K | 0.01% | 336 |
|
|
2015
Q2 | – | Sell |
-5,102
| Closed | -$56K | – | 4578 |
|
|
2015
Q1 | $56K | Buy |
+5,102
| New | +$45K | 0.01% | 1378 |
|
|
2014
Q4 | – | Sell |
-4,000
| Closed | -$24K | – | 4217 |
|
|
2014
Q3 | $24K | Buy |
4,000
+1,693
| +73% | +$8.87K | ﹤0.01% | 2150 |
|
|
2014
Q2 | $8K | Sell |
2,307
-1,430
| -38% | -$3.36K | ﹤0.01% | 2512 |
|
|
2014
Q1 | $8K | Sell |
3,737
-456
| -11% | -$1.14K | ﹤0.01% | 2814 |
|
|
2013
Q4 | $10K | Sell |
4,193
-1,958
| -32% | -$4.3K | ﹤0.01% | 2970 |
|
|
2013
Q3 | $14K | Buy |
+6,151
| New | +$15.4K | ﹤0.01% | 2953 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Tower Research Capital (TRC)'s FOLD Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Amicus Therapeutics (FOLD) stake by 1,751% in Q1 2026, buying an estimated $593K and bringing the position to 43,730 shares worth $632K. The position accounts for 0.02% of the portfolio, ranked #761.
Tower Research Capital (TRC) first reported a position in FOLD in Q3 2013 and has held it in 39 quarters since. The position peaked at $921K in Q3 2022. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Tower Research Capital (TRC) held 43,730 shares of Amicus Therapeutics worth $632K as of Q1 2026.
- Tower Research Capital (TRC) bought 41,367 Amicus Therapeutics shares in Q1 2026, an estimated $593K.
- Amicus Therapeutics made up 0.02% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #761 holding.
- Tower Research Capital (TRC) first reported a position in Amicus Therapeutics in Q3 2013 and has held it in 39 quarters since.
- Tower Research Capital (TRC)'s Amicus Therapeutics position peaked at $921K in Q3 2022.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.